Adrenergic alpha-1 Receptor Antagonists

Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS.

Also Known As:

Adrenergic alpha-1 Antagonists; Adrenergic alpha-1 Receptor Blockers; Adrenergic alpha1-Antagonists; alpha-1 Adrenergic Blocking Agents; alpha1-Adrenergic Antagonists; alpha1-Adrenoceptor Blocker; Adrenergic alpha 1 Antagonists; Adrenergic alpha 1 Receptor Antagonists; Adrenergic alpha 1 Receptor Blockers; Adrenergic alpha1 Antagonists; Antagonists, alpha1-Adrenergic; alpha 1 Adrenergic Blocking Agents; alpha-1 Antagonists, Adrenergic; alpha1 Adrenergic Antagonists; alpha1 Adrenoceptor Blocker; alpha1-Antagonists, Adrenergic

Networked: 28 relevant articles (8 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Adrenergic Agents: 9549
        Adrenergic Antagonists: 736
        Adrenergic alpha-Antagonists: 133
        Adrenergic alpha-1 Receptor Antagonists: 28
  - Physiological Effects of Drugs: 1
    - Neurotransmitter Agents: 13181
      - Adrenergic Agents: 9549
        Adrenergic Antagonists: 736
        Adrenergic alpha-Antagonists: 133
        Adrenergic alpha-1 Receptor Antagonists: 28

Experts

1.	Tarter, T H: 2 articles (01/2009 - 01/2006)
2.	Maisch, Nicole: 1 article (06/2022)
3.	Saad, Maha: 1 article (06/2022)
4.	Gagnier, Joel J: 1 article (01/2020)
5.	Lee, John J: 1 article (01/2020)
6.	Pour, Aidin Eslam: 1 article (01/2020)
7.	Schubert, Manuel F: 1 article (01/2020)
8.	Thomas, Jared R: 1 article (01/2020)
9.	Urquhart, Andrew G: 1 article (01/2020)
10.	Yashar, Jacob: 1 article (01/2020)

Related Diseases

1.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 09/01/2007 - "[Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension]." 06/01/2022 - "It is thought to be associated with adrenergic alpha-1 receptor antagonists commonly used to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. " 01/01/2010 - "Alpha1-adrenergic antagonists relieve lower urinary tract symptoms related to benign prostatic hyperplasia. " 04/01/2009 - "Among patients with benign prostatic hyperplasia who were treated with a alpha1-adrenoceptor blocker, we administered naftopidil (75 mg/day) for 12 weeks to 85 patients in whom the global severity was evaluated as moderate or severe. " 05/01/2008 - "[Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker]."
2.	Lower Urinary Tract Symptoms 02/01/2009 - "Prior studies have shown significant improvement in lower urinary tract symptoms with alpha1-adrenergic antagonists. " 06/01/2022 - "It is thought to be associated with adrenergic alpha-1 receptor antagonists commonly used to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. " 01/01/2010 - "Alpha1-adrenergic antagonists relieve lower urinary tract symptoms related to benign prostatic hyperplasia. " 05/01/2008 - "We examined the effectiveness of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia (BPH) whose lower urinary tract symptoms (LUTS) caused by BPH were not adequately relieved by an alpha1-adrenoceptor blocker. " 04/01/2008 - "Clinical data suggest that the addition of alpha1-adrenoceptor blocker, such as alfuzosin, commonly prescribed for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, may be of benefit. "
3.	Urinary Retention 01/01/2018 - "Prophylactic use of alpha-1 adrenergic blocking agents for prevention of postoperative urinary retention: A review & meta-analysis of randomized clinical trials." 01/01/2009 - "Clinical trials have shown that alpha1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. " 01/01/2007 - "Clinical trials have shown that alpha1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. " 01/01/2020 - "The purpose of this study was to determine whether male patients taking pre-operative selective alpha-1 adrenergic blocking agents have a lower likelihood of developing post-operative urinary retention (POUR) and a shorter length of hospitalization following lower extremity arthroplasty. " 01/01/2020 - "Post-operative urinary retention after lower extremity arthroplasty and the peri-operative role of selective alpha-1 adrenergic blocking agents in adult male patients: a propensity-matched retrospective cohort study."
4.	Hypertension (High Blood Pressure) 09/01/2007 - "The article reviews the progress in the studies of alpha1-adrenoceptor blocker for BPH associated hypertension, and explores the main problems facing us and ventures the prospects for the development in this field." 06/01/1990 - "The use of alpha 1 adrenergic blocking agents for hypertension." 09/01/2007 - "[Progress in the studies of alpha1-adrenoceptor blocker for concurrent benign prostatic hyperplasia and hypertension]." 06/01/2022 - "Data Synthesis Numerous reports have linked IFIS to multiple risk factors including age, gender, hypertension, and the use of adrenergic alpha-1 receptor antagonists, most notably tamsulosin. " 07/01/1993 - "The JNC V report has also added alpha-1 adrenergic blocking agents and the alpha-beta blocker labetalol to the list of drugs suitable for initial monotherapy in managing hypertension."
5.	Nocturia 03/01/2008 - "Supplemental administration of flavoxate hydrochloride is therefore effective for the improvement of nocturia and QOL in BPH patients resistant to an alpha1-adrenoceptor blocker." 03/01/2008 - "We examined the effectiveness of supplemental administration of flavoxate hydrochloride in patients with benign prostatic hyperplasia (BPH) whose nocturia was not adequately relieved by an alpha1-adrenoceptor blocker. " 03/01/2008 - "[Clinical evaluation of supplemental administration of flavoxate hydrochloride in benign prostatic hyperplasia patients with nocturia resistant to an alpha1-adrenoceptor blocker]."

Related Drugs and Biologics

1.	Doxazosin (Cardura)
2.	Antihypertensive Agents (Antihypertensives)
3.	Tamsulosin (Flomax)
4.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
5.	Antipsychotic Agents (Antipsychotics)
6.	Flavoxate (Urispas)
7.	Benzodiazepines
8.	Anticonvulsants (Antiepileptic Drugs)
9.	Anti-Bacterial Agents (Antibiotics)
10.	eviprostat

Related Therapies and Procedures

1.	Therapeutics
2.	Lithotripsy (Extracorporeal Shockwave Lithotripsy)
3.	Arthroplasty
4.	Ligation
5.	Injections